According to Zacks, “BioXcel Therapeutics Inc. is a clinical stage biopharmaceutical company. It focuses on drug development which utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology. The company’s product portfolio include BXCL501, a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer. BioXcel Therapeutics Inc. is based in the United States. “
A number of other research analysts have also recently weighed in on BTAI. HC Wainwright set a $25.00 price objective on shares of BioXcel Therapeutics and gave the company a buy rating in a research report on Wednesday, June 5th. ValuEngine cut shares of BioXcel Therapeutics from a buy rating to a hold rating in a research report on Monday, July 8th.
BioXcel Therapeutics (NASDAQ:BTAI) last posted its quarterly earnings data on Tuesday, May 7th. The company reported ($0.46) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.48) by $0.02. As a group, equities analysts anticipate that BioXcel Therapeutics will post -2.19 earnings per share for the current year.
An institutional investor recently bought a new position in BioXcel Therapeutics stock. Creative Planning bought a new stake in shares of BioXcel Therapeutics Inc (NASDAQ:BTAI) in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 30,550 shares of the company’s stock, valued at approximately $302,000. Creative Planning owned 0.20% of BioXcel Therapeutics at the end of the most recent quarter. 16.11% of the stock is owned by institutional investors and hedge funds.
BioXcel Therapeutics Company Profile
BioXcel Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent designed for the treatment of prostate and pancreatic cancers.
Further Reading: What is the price-to-earnings growth (PEG) ratio?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioXcel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioXcel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.